Vaxcyte Appoints Jacks Lee to Board of Directors
28 November 2023 - 2:30PM
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company
engineering high-fidelity vaccines to protect humankind from the
consequences of bacterial diseases, today announced the appointment
of Jacks Lee to its Board of Directors.
“We are pleased to welcome Jacks, an accomplished industry
leader with extensive biopharmaceutical and vaccine manufacturing,
supply and operations expertise, to Vaxcyte’s Board of Directors as
we continue to realize our mission of developing vaccines to
address serious bacterial illnesses,” said Grant Pickering, Chief
Executive Officer and Co-founder of Vaxcyte. “Jacks will provide
strategic insights across many aspects of our business, including
commercialization, supply chain and manufacturing, as we advance
our pipeline and work toward the potential global commercialization
of our pneumococcal conjugate vaccine (PCV) candidates, VAX-24 and
VAX-31.”
“I am honored to join Vaxcyte’s Board of Directors,” said Mr.
Lee. “I believe the Company has the potential to deliver a
best-in-class PCV franchise and I look forward to sharing my
knowledge about the global commercialization and supply of vaccines
as the VAX-24 and VAX-31 clinical programs continue to
progress.”
About Mr. Lee Mr. Lee’s esteemed career in the
biopharmaceutical industry includes more than 30 years of
experience having led global strategic supply and manufacturing
operations at leading multi-national pharmaceutical companies, with
a significant focus on vaccines and biopharmaceuticals. His
experience spans technical, operational and strategic leadership
roles in engineering, quality, supply chain and manufacturing. Most
recently, Mr. Lee was Senior Vice President of Global Manufacturing
and Supply at Merck & Co., Inc., with responsibility for the
division that manufactures and supplies vaccines and biologics
globally. Previously, during his nearly 20-year tenure at Sanofi,
Mr. Lee held various leadership positions, including Head of
Manufacturing Vaccines and Biologics Operations. Mr. Lee earned his
Master of Science in Industrial Management from the University of
Central Missouri and his Bachelor of Science in Industrial
Engineering from the University of Wisconsin-Madison. Mr. Lee also
serves on the Board of Directors of G1 Therapeutics, Inc.
About VaxcyteVaxcyte is a vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases. The Company is
developing broad-spectrum conjugate and novel protein vaccines to
prevent or treat bacterial infectious diseases. Vaxcyte’s lead
candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing
PCV being developed for the prevention of invasive pneumococcal
disease and is poised to move into Phase 3. VAX-31, the Company’s
next-generation, 31-valent PCV candidate, is the broadest-spectrum
PCV in the clinic today.
Vaxcyte is re-engineering the way highly complex vaccines are
made through modern synthetic techniques, including advanced
chemistry and the XpressCF™ cell-free protein synthesis platform,
exclusively licensed from Sutro Biopharma, Inc. Unlike conventional
cell-based approaches, the Company’s system for producing
difficult-to-make proteins and antigens is intended to accelerate
its ability to efficiently create and deliver high-fidelity
vaccines with enhanced immunological benefits. Vaxcyte’s pipeline
also includes VAX-A1, a prophylactic vaccine candidate designed to
prevent Group A Strep infections; VAX-PG, a therapeutic vaccine
candidate designed to slow or stop the progression of periodontal
disease; and VAX-GI, a vaccine program designed to prevent
Shigella. Vaxcyte is driven to eradicate or treat invasive
bacterial infections, which have serious and costly health
consequences when left unchecked. For more information, visit
www.vaxcyte.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. These statements
include, but are not limited to, statements related to the
potential benefits of VAX-31 and VAX-24, including the ability to
deliver potentially best-in-class profiles; the ability of Vaxcyte
to develop vaccines that address serious bacterial illnesses; the
ability of Vaxcyte to globally commercialize its PCV candidates;
the timing of the VAX-24 Phase 3 clinical study in adults; and
other statements that are not historical fact. The words
“anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “on
track,” “potential,” “should,” “would” and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) convey uncertainty of future events or
outcomes and are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are based
on Vaxcyte’s current expectations and actual results and
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of risks and
uncertainties, including, without limitation, risks related
to Vaxcyte’s product development programs, including
development timelines, success and timing of chemistry,
manufacturing and controls and related manufacturing activities,
potential delays or inability to obtain and maintain required
regulatory approvals for its vaccine candidates, and the risks and
uncertainties inherent with preclinical and clinical development
processes; the success, cost and timing of all development
activities and clinical trials; and sufficiency of cash and other
funding to support Vaxcyte’s development programs and other
operating expenses. These and other risks are described more fully
in Vaxcyte’s filings with the Securities and Exchange Commission
(SEC), including its Quarterly Report on Form 10-Q filed with the
SEC on November 6, 2023 or in other documents Vaxcyte subsequently
files with or furnishes to the SEC. All forward-looking statements
contained in this press release speak only as of the date on which
they were made and are based on management’s assumptions and
estimates as of such date, and readers should not rely upon the
information in this press release as current or accurate after its
publication date. Vaxcyte undertakes no duty or obligation to
update any forward-looking statements contained in this release as
a result of new information, future events or changes in its
expectations. Readers should not rely upon the information in this
press release as current or accurate after its publication
date.
Contacts:
Janet Graesser, Vice President, Corporate Communications and
Investor RelationsVaxcyte, Inc.917-685-8799media@vaxcyte.com
Jennifer Zibuda, Senior Director, Investor Relations Vaxcyte,
Inc.860-729-8902investors@vaxcyte.com
Vaxcyte (NASDAQ:PCVX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Vaxcyte (NASDAQ:PCVX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024